Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06551727
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
None
First Post:
2024-08-06
Brief Title:
Antithrombotic Therapy With Regulation of Blood Pressure in Non-Cardioembolic Progressive Stroke
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Antithrombotic Therapy With Regulation of Blood Pressure in Non-Cardioembolic Progressive Stroke
Status:
ENROLLING_BY_INVITATION
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Stroke has become the leading cause of death in China with acute ischemic stroke still progressing within one week of onset known as progressive ischemic stroke PIS which has a high rate of disability and mortality accounting for 23-43 of the incidence of stroke Non-cardioembolic PIS is one of the common types and the current treatment mainly focuses on antithrombotic therapy but the therapeutic effect is not satisfactory More and more evidence suggests that hypotension is an unfavorable factor for PIS so this study intends to explore the efficacy and safety of antithrombotic therapy with regulation of blood pressure in non-cardioembolic PIS
Detailed Description:
This is a single-center randomized controlled study conducted to explore the efficacy and safety of antithrombotic therapy with regulation of blood pressure in non-cardioembolic PIS
We plan to recruit 70 patients with non-cardioembolic PIS All subjects are of Han ethnicity aged 18 years or older Gender and age will be statistical data after enrollment Patients will participate in the study after informed consent
Then patients who meet the inclusion and exclusion criteria will be randomly assigned in a 11 ratio to the control group antithrombotic therapy or the intervention group antithrombotic blood pressure control therapy In addition to antithrombotic therapy the intervention group will use medications such as dopamine metaraminol or midodrine to control systolic blood pressure within the range of 160-180 mmHg and maintain it for one week
Patients will be followed up at 2 weeks for mRS Modified Rankin Scale and NIHSS National Institutes of Health Stroke Scale scoresand at one month for mRS scores and at three months for mRS and BI Barthel Index scores
We plan to recruit 70 patients with non-cardioembolic PIS All subjects are of Han ethnicity aged 18 years or older Gender and age will be statistical data after enrollment Patients will participate in the study after informed consent
Then patients who meet the inclusion and exclusion criteria will be randomly assigned in a 11 ratio to the control group antithrombotic therapy or the intervention group antithrombotic blood pressure control therapy In addition to antithrombotic therapy the intervention group will use medications such as dopamine metaraminol or midodrine to control systolic blood pressure within the range of 160-180 mmHg and maintain it for one week
Patients will be followed up at 2 weeks for mRS Modified Rankin Scale and NIHSS National Institutes of Health Stroke Scale scoresand at one month for mRS scores and at three months for mRS and BI Barthel Index scores
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None